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Coarse structural nested mean models are used to estimate treatment ef-
fects from longitudinal observational data. Coarse structural nested mean
models lead to a large class of estimators. It turns out that estimates and
standard errors may differ considerably within this class. We prove that,
under additional assumptions, there exists an explicit solution for the op-
timal estimator within the class of coarse structural nested mean models.
Moreover, we show that even if the additional assumptions do not hold,
this optimal estimator is doubly-robust: it is consistent and asymptotically
normal not only if the model for treatment initiation is correct, but also
if a certain outcome-regression model is correct. We compare the optimal
estimator to some naive choices within the class of coarse structural nested
mean models in a simulation study. Furthermore, we apply the optimal and
naive estimators to study how the CD4 count increase due to one year of
antiretroviral treatment (ART) depends on the time between HIV infection
and ART initiation in recently infected HIV infected patients. Both in the
simulation study and in the application, the use of optimal estimators leads
to substantial increases in precision.
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The effect of time-dependent treatments is often estimated from observa-
tional data, since clinical trials where treatment is repeatedly randomized
are not common. Estimating treatment effects from observational data
is more difficult than from clinical trials. Since treatment was not ran-
domized, patients receiving treatment typically have different pre-treatment
character-istics than patients not receiving treatment, leading to confound-
ing by indica-tion. If patients with a worse prognosis were treated more
often, a naive analysis would lead to underestimation of the treatment ef-
fect. It could even reverse the sign of the treatment effect, as illustrated
for time-dependent treatments in an HIV example in Lok and DeGruttola
(2012).
Several approaches exist to estimate treatment effects from longitudinal
observational data. Time-dependent coarse structural nested mean models
(coarse SNMMs) describe the effect of time-dependent treatments, condi-
tional on patient characteristics at the time of treatment initiation. Coarse
SNMMs model the mean difference between the outcome with treatment
initiated at time m, versus never, on the outcome measured at a later time
k, given a patient was not treated until time m, and given a patient’s co-
variate history at time m (Lok and DeGruttola 2012). Previously, Robins
(1998a) introduced coarse SNMMs for outcomes measured at the end of a
study, for trials with noncompliance. Earlier SNMMs studied in Robins
et al. (1992), Mark and Robins (1993), Lok et al. (2004), and Robins (1994)
describe the effect of one treatment dosage conditional on patient charac-
teristics just prior to this dosage. Estimating the effect of a longer duration
of treatment from these quantities requires modeling the distribution of co-
variates given past treatment and covariate history, possibly leading to bias
(Robins 1986, 1987, 1989, 1994), or even incompatibility of the different as-
sumptions (Robins 1994). Coarse structural nested mean models are thus
useful to estimate the effect of a treatment that is initiated once and then
never stopped, since they directly estimate the effect of multiple treatment
dosages.
Marginal structural models (Robins et al. 2000, Hernán et al. 2000)
are another class of models to estimate the effect of time-dependent treat-
ments from observational data. Marginal structural models estimate how
treatment effects depend on baseline, but not time-dependent, covariates.
Robins (2000) provides a detailed comparison of marginal structural mod-
els and structural nested models. Q-learning (Chakraborty and Murphy
2014, Nahum-Shani et al. 2012) also estimates treatment effects from time-
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dependent observational data (and SMART trials, where treatments are
repeatedly randomized). Q-learning builds on classical dynamic program-
ming: 1. estimate the optimal last treatment strategy; 2., with backwards
induction, the optimal treatment strategy at each time point given the op-
timal treatment strategy will be followed onwards. Q-learning is thus aimed
at estimating optimal treatment regimes, and does not focus on the effect
of a fixed duration of treatment, or of treatment initiation at different time
points. As traditional SNMMs, Almirall et al. (2013) estimate the effect of
a last blip of treatment conditional on a covariate and treatment history,
and how this effect depends on potential effect modifiers, while allowing for
confounders one might not want to estimate the effect modification of. They
do not cover optimal estimation.
SMART trials (Chakraborty and Murphy 2014, Almirall et al. 2014)
determine the best time-dependent treatment strategies using randomized
trials. In SMART trials, baseline and subsequent treatment decisions are
randomized, with randomizaton options determined by prior outcomes. Liu
et al. (2018) combine outcome weighted learning with Q-learning to solve the
optimal treatment strategy from SMART trials. They use support vector
machines after a reformulation of the expected utility under any treatment
strategy that leads to a convex optimization problem.
Various methods have been proposed to efficiently estimate the effect of
point treatments. Newey (1993) describes efficient estimation under con-
ditional moment restrictions. Our identifying assumption leads to a con-
ditional mean being independent of a time-dependent treatment variable,
which cannot be written in terms of such a conditional moment restriction,
so the theory from Newey (1993) cannot be applied to derive efficient esti-
mators of coarse structural nested models. There are similarities between
our work and Newey (1993) in that we are deriving an optimal “instrumental
variable” in the sense of the econometrics literature: a function of the covari-
ates which leads to the smallest asymptotic variance. Targeted maximum
likelihood estimation (TMLE: Van der Laan and Rubin 2006) is a method
for doubly robust and efficient estimation of parameters in several semi-
parametric and nonparametric settings. Later targeted maximum likelihood
estimation theory (Van der Laan and Gruber 2012, Schnitzer et al. 2014,
Petersen et al. 2014) builds on theory from Bang and Robins (2005). Tar-
geted maximum likelihood estimation has not been developed for structural
nested models. Tsiatis (2006) covers semiparametric efficient estimation,
but not of structural nested models. Tsiatis (2006) focuses on missing data
problems, which could potentially be adapted easier to marginal structural
models (Robins et al. 2000, Hernán et al. 2000), which use inverse prob-
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ability of treatment weighting. Inverse probability of treatment weighting
methods are also advocated in Chakraborty and Murphy (2014). Matching
(Imbens 2004, Rosenbaum 2017) has been restricted to baseline treatments,
not time-dependent treatments, and the most commonly used version with
a fixed number of matches per individual is not efficient (Abadie and Im-
bens 2006). Gutman and Rubin (2013) describe the effect of a point treat-
ment on a binary outcome Y in the presence of one continuous confounder
X. They use EY = EE[Y |X] for Y the outcome under no treatment and
for Y the outcome under treatment (see also Bang and Robins 2005 Sec-
tion 2.1). Gutman and Rubin (2013) estimate the conditional expectations
separately for treatment and control with splines, and use multiple imputa-
tion instead of the estimated conditional means. This method is not doubly
robust or efficient (Bang and Robins 2005). Hahn (1998) proposed efficient
methods to estimate the effect of point treatments from observational data.
His proposed imputation methods are hard to generalize to time-dependent
treatments, where if there are K potential treatment times, the number
of missing potential outcomes per patient is 2K − 1. In addition, it seems
easier to specify the treatment initiation models than the models for the con-
ditional expectations of the outcomes. The theory of Chernozhukov et al.
(2015) Section 3 on optimal variance does not apply to coarse structural
nested mean models, since, as we will show, coarse structural nested mean
models lead to a continuum of (orthogonal) unbiased estimating equations
for the causal parameter of interest.
In contrast to most of the literature on efficient estimation of treatment
effects from observational data (Imbens 2004 provides an overview), this
article focuses on optimal estimation of the effect of a time-dependent treat-
ment. In addition, coarse structural nested mean models can estimate how
the treatment effect depends on time-dependent pre-treatment characteris-
tics, which is not the focus of most of the literature on efficient estimation
of treatment effects.
We provide a description of the estimation methods and the assumptions
needed to consistently estimate coarse structural nested mean models (coarse
SNMMs) with an outcome measured over time. Detailed proofs are in Lok
and DeGruttola (2012), Robins (1994), and Robins et al. (1999). The main
focuses of this article however are double robustness and optimal estimation.
Robins (1998a) and, for time-dependent outcomes, Lok and DeGruttola
(2012) derived a large class of estimating equations for coarse SNMMs, all
leading to consistent, asymptotically normal estimators for the treatment
effect. It turns out that both estimates and standard errors may depend
considerably on the choice of estimating equations within this large class.
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This motivates the current article, which derives, under extra conditions, an
optimal choice of estimators within a class that includes the estimators from
Lok and DeGruttola (2012). This optimal estimator leads to the smallest
possible asymptotic variance. It is also doubly robust: it is consistent and
asymptotically normal not only if the model for treatment initiation is cor-
rectly specified, but also if a certain outcome-regression model is correctly
specified. The optimal estimator combines weighting and regression, and is
therefore a mixed method (compare with mixed methods for point exposures
described in Imbens 2004).
Also without the extra conditions needed for optimality and in the pres-
ence of censoring, this optimal estimator is doubly robust; it just may not
be optimal in such settings. As shown in Application Section 9, the opti-
mal estimator may perform considerably better than arbitrarily choosing an
estimator within the class of coarse SNMMs.
We implemented the proposed optimal estimator and compare it to other
estimators for coarse SNMMs, both in a simulation study and in an HIV
application.We estimate how the effect of one year of ART, the current
standard of care for HIV infected patients, depends on the time between
the estimated date of HIV infection and ART initiation. The application
includes correction for informative censoring, and bootstrap confidence in-
tervals. Consistency of the bootstrap for all our estimators is proven in
Web-appendix A under regularity conditions.
Optimality for coarse SNMMs is simpler than optimality for more tradi-
tional SNMMs (see Robins 1994, Van der Laan and Robins 2003), because
coarse SNMMs avoid the need for accumulating the effects over time. This
article therefore includes an accessible illustration of the steps involved in
calculating optimal estimators. Our Web-Appendix explicitly proves all our
results for time-dependent coarse SNMMs, thus providing a self-contained
example.
2 Setting and notation
Initially, all patients are assumed to be followed at the same times 0, 1, . . . ,K+
1, with 0 indicating the baseline visit. The assumption that there is no cen-
soring due to loss-to-follow-up is relaxed in Section 7. Yk is the outcome
at time k. Y k = (Y0, Y1, . . . , Yk) is the outcome history until time k. Ak
is the treatment at time k. We investigate the effect of a binary treatment
Ak, which is either given (Ak = 1) or not (Ak = 0) at each time k. Ak
is the treatment history until time k. We only consider the impact of ini-
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tiating treatment, and do not consider issues of treatment interruption or
compliance: our analysis follows the intention-to-treat principle common in
randomized trials. Thus, Ak = 0 until treatment is initiated, and Ak = 1
thereafter. T is the time treatment was actually initiated, with T = K + 1
if treatment was never initiated. Similarly, Lk are the covariates at time k,
including the outcome Yk at time k, and Lk is the covariate history until
time k. Lk is the space in which Lk takes its values. We assume that at
each visit time k, treatment decisions Ak are made after Lk is measured and
known. We suppress patient-level notation (such as the subscript i often





k are the counterfactual, not always measured, outcome





k are the covariates and covariate history at time k under the
treatment regime “no treatment”. Y
(m)
k is the outcome at time k under the
treatment regime “start treatment at time m”. We assume that observations
and counterfactuals of the different patients are independent and identically
distributed (Rubin 1978).
3 Time-dependent coarse structural nested mean
models
Our model for treatment effect is similar to that in Robins (1998a), but
differs in that we allow a time-dependent outcome, as in Lok and DeGruttola
(2012):
Definition 3.1 (TIME-DEPENDENT COARSE SNMMS).




















is the expected difference, for patients whose treatment started at
time m with covariates lm, of the outcome at time k had the patient started
treatment at time m, and the outcome at time k had the patient never
started treatment. It is the effect of treatment between times m and k.
We assume a parametric model for the treatment effect γ, leading to
a semiparametric setting. γ models the expected difference between two
counterfactual outcomes. How any of these outcomes depends on a patient’s
covariates at timem is not specified. For example, it could be that, for k > m
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(note that k −m is the treatment duration until time k), with
E[ε
(m)
k | Lm, T = m] = 0 and E[ε
(∅)
k | Lm, T = m] = 0. In this example,





















, but rank preser-
vation has been argued to not hold in many practical applications (Robins
1998b, Lok 2017). A coarse SNMM is a model for the effect of the treatment
on the treated, as discussed in e.g. Imbens (2004). If L contains enough in-
formation to make those treated and those untreated at time m comparable
given Lm, a structural nested mean model is also a model for the effect of
the treatment on all patients with given covariates Lm. The lack of dis-
tinction between the effect of the treatment on the treated and the effect of
the treatment is due to the fact that structural nested models condition on
pre-treatment covariates.









, with ψ a parameter in
Rp and ψ∗ the true parameter.
The following example (Lok and DeGruttola 2012) motivated this work on
optimal estimation:
Example 3.3 (Effect of antiretroviral treatment (ART) depending on the
time between estimated date of HIV infection and treatment initiation in











with (k−m) the treatment duration from month m to month k, is a correctly
specified parametric model. Possibly, the mean treatment effect also depends
non-linearly on the treatment duration. In that case, one could add non-
linear terms such as ψ4(k−m)21{k>m}, or additionally include a non-linear
term depending on time since infection, such as (ψ4 +ψ5m)(k−m)21{k>m}.
The treatment effect γ may also depend on pre-treatment covariates, such
as log10 HIV viral load in the blood (lvl), resistance mutations, and the CD4
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count. To incorporate pre-treatment covariates such as log10 HIV viral load,
one can extend the model by including terms such as ψ4lvlm(k−m)1{k>m}.
We chose some function of (k −m) because the treatment duration may be
predictive of its effect. If, for example, the treatment effect depends only on
the viral load at treatment initiation for the first month of treatment, one
might add terms such as ψ4lvlm1{k>m}.
Following Robins et al. (1992) and Robins (1994), we use the propensity
score (Rosenbaum and Rubin 1983), the prediction of treatment given the
past, p(m) = pr
(
Am = 1 | Am−1 = 0, Lm
)
, to estimate the treatment effect
γ. Henceforth, we assume that pθ(m) is a correctly specified model for
p(m), with p(m) = pθ∗(m). We typically estimate θ∗ by maximum partial
likelihood.
4 No unmeasured confounding and consistency
As in Robins et al. (1992), Robins (1998b), Robins et al. (2000), Lok et al.
(2004), Robins (1998a), and Lok and DeGruttola (2012), to distinguish be-
tween treatment effect and confounding by indication, we require the as-
sumption of no unmeasured confounding. It states that information is avail-
able on all factors that both: (1) influence treatment decisions and (2) pos-
sibly predict a patient’s prognosis with respect to the outcome of interest.
Y
(∅)
k , the outcome at time k without treatment, reflects a patient’s prog-
nosis with respect to the outcome of interest. If there is no unmeasured
confounding, treatment decisions at time m (Am) are independent of this
(not always measured) prognosis Y
(∅)
k (k > m), given past treatment and
covariate history Am−1 and Lm:
Assumption 4.1 (No unmeasured confounding - formalization). Am⊥⊥Y (∅)k |
Lm, Am−1 for k > m, where ⊥⊥ means: is independent of (Dawid (1979)).
If a patient is not treated until time k, there is no difference in treat-
ment between Yk and Y
(∅)
k . In this and similar cases, it is reasonable to
assume that until time k, the observed outcomes and the outcomes without
treatment would have been the same:
Assumption 4.2 (Consistency). If T ≥ k, Yk = Y (∅)k and Lk = L
(∅)
k .
Y (T ) = Y .
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5 Estimation: unbiased estimating equations
This section describes the estimation methods from Robins (1998a) and Lok
and DeGruttola (2012). Proofs can be found in Lok and DeGruttola (2012).




. On k ≤ T , define
H(k) = Yk.
Example 5.2 (Effect of antiretroviral treatment (ART) depending on the
time between estimated date of HIV infection and treatment initiation in
HIV infected patients). In the setting of Example 3.3, on k > T , H(k) =
Yk −
(
ψ1 + ψ2T + ψ3T
2
)
(k − T ).




= H(k). This so-called blipping
off of the treatment effect generates a random variable H(k) that mimics a
counterfactual outcome:
Theorem 5.3 (MIMICKING COUNTERFACTUAL OUTCOMES). Un-
der consistency assumption 4.2, for m ≤ K and k ≥ m,
E
[






k | Lm, Am−1 = 0, Am
]
.
The idea behind estimation, similar to for example Robins et al. (1992)
or Lok et al. (2004), is that under assumption of no unmeasured confound-
ing 4.1, given past treatment and covariate history, Y
(∅)
k does not help to pre-
dict treatment changes. In other words, in the model for treatment changes,
that is, the propensity score (Rosenbaum and Rubin 1983), Y
(∅)
k does not
contribute. Lok and DeGruttola (2012) proved that because of Theorem 5.3,
the same holds for Hψ∗ (k), and that similar to Lok (2008, 2007), this leads
to the following theorem:
Theorem 5.4 (UNBIASED ESTIMATING EQUATIONS). Suppose that
consistency assumption 4.2 and assumption of no unmeasured confound-
ing 4.1 hold. Consider any ~q km : Lm → Rp, m = 0, . . . ,K, k > m, which are











H (k) 1Am−1=0 {Am − p (m)}
)
= 0.
If furthermore γψ is correctly specified (Assumption 3.2) and pθ (m) correctly















stacked with the estimating equations for θ∗, with Pn the empirical measure
Pn(X) = 1/n
∑n
i=1Xi, are unbiased estimation equations for (ψ, θ). The
~q km here are allowed to depend on (ψ, θ), as long as they are measurable and
bounded for (ψ∗, θ∗).
For identifiability of the estimator, one needs as many estimating equations
as parameters, in this case by choosing the dimension of ~q. Including k ≤ m
does not help in these estimating equations, since for those k, on Am−1 = 0,
Hψ(k) = Y
(∅)
k = Yk, which is part of Lm and therefore generates a term with
expectation 0 regardless of ψ.
If γ is linear in ψ, this approach leads to a linear restriction on ψ once
the parameter θ has been estimated, and thus to a closed form expression
for ψ̂.
6 Optimal estimating equations
6.1 Assumptions and restrictions on the estimating equa-
tions
The vast literature on unbiased estimating equations, see e.g. Van der Vaart
(1998) Chapter 5, indicates that under regularity conditions, ψ̂ is consistent
and asymptotically normal for any choice of ~q with the same dimension as ψ.
Under those regularity conditions, the asymptotic variance of an estimator































+ oP (1). (3)
In the following we restrict to estimators that satisfy the regularity con-
ditions needed for (3) and thus (2) to hold. Among such estimators, this
article derives the optimal choice of ~q. The remainder of this article also
assumes assumption of no unmeasured confounding 4.1, consistency assump-
tion 4.2, and correct specification of coarse structural nested mean model
assumption 3.2. Web-Appendix A provides proofs of all theorems and lem-
mas. Web-Appendix A shows, under regularity conditions, consistency of
the bootstrap for all estimators considered.
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6.2 Doubly robust estimators lead to increased precision
Definition 6.1 Let









Hψ(k)1Am−1=0 {Am − pθ(m)} ,











Hψ(k) | Lm, Am−1 = 0
]}
1Am−1=0 {Am − pθ(m)} .
First, we consider estimating equations for ψ when θ∗ and thus the
propensity score is known:
Theorem 6.2 (REPLACEMENT OF ESTIMATING EQUATIONS BY
MORE EFFICIENT ONES). Under no unmeasured confounding assump-
tion 4.1, consistency assumption 4.2 and the usual regularity conditions for
the sandwich estimator for the variance, based on equation (2), to hold,
Pn
(
G∗ (ψ, θ∗, q)
)
= 0 are unbiased estimating equations which, for given ~q,
lead to a smaller asymptotic variance of ψ̂ than the estimating equations
Pn (G(ψ, θ∗, q)) = 0.
The equations with G∗ are not true estimating equations, because their
specification depends on the parameter ψ of interest, through the conditional
expectation of Hψ. We will return to this issue later. Theorem 5.3 facilitates
specifying the model for the conditional expectation of H.
In practice, θ∗ will usually be unknown and has to be estimated. For the
more efficient estimators based on G∗ of Theorem 6.2, estimating θ∗ does not
change the asymptotic variance of ψ̂. This result is similar to Proposition 1
in Rotnitzky and Robins (1995) for a missing data problem:
Theorem 6.3 Replacement of θ∗ by θ̂ from a correctly specified pooled logis-







= 0, leads to the same asymptotic variance for ψ̂ as
the estimator for ψ∗ that solves Pn
(
G∗ (ψ, θ∗, q)
)
= 0.
For the estimators solving Pn (G(ψ, θ∗, q)) = 0, estimating θ∗ may change
the asymptotic variance. It usually reduces the asymptotic variance, as was
also seen in Robins (2004) and Lok (2008) for different structural nested
models. However, the resulting estimator is never more efficient than its
doubly robust counterpart:
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Theorem 6.4 For q fixed, replacement of θ∗ by θ̂ from a correctly specified
pooled logistic regression model fitted by maximum partial likelihood does not






= 0 more efficient







As for SNMMs (Robins 2004, 3.10 page 23), estimators resulting from G∗
are also doubly robust:







= 0 is doubly robust: stacked with the estimating equa-
tions for θ, these estimating equations are unbiased for ψ if either pθ or
E
[
Hψ(k) | Lm, Am−1 = 0
]
is correctly specified. Thus, ψ̂ is consistent and
asymptotically normal if either of these models is correctly specified.
It follows that both for robustness and for efficiency, the estimators with G∗
are preferred.
6.3 A theorem that guarantees optimality of estimators
The following theorem, a consequence of Theorem 5.3 from Newey and Mc-
Fadden (1994), gives a sufficient criterion under which ~q opt is optimal within
our two classes of estimating equations, described by G and G∗:
Theorem 6.6 (SUFFICIENT OPTIMALITY CRITERION WITH θ∗ KNOWN).
For both G and G∗: if ~q opt satisfies
E
(










then no other ~q satisfying our regularity conditions within this class leads
to an estimator for ψ∗ with a smaller asymptotic variance than ~q
opt. The













. There is a unique (in L2(P )-sense)
optimal solution to equation (4) within this class of estimating equations.
6.4 Explicit expression for optimal estimating equations for
coarse SNMMs with a time-varying outcome
This section finds the optimal ~q under the following condition:
Assumption 6.7 (Homoscedasticity). For 0 ≤ m ≤ K and k, s > m,
cov
[
H(k), H(s) | Lm, Am−1 = 0, Am
]
does not depend on Am.
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Assumption 6.7 is a homoscedasticity assumption, because it states that a
conditional covariance does not depend on Am. Because of Theorem 5.3
and no unmeasured confounding assumption 4.1, homoscedasticity assump-
tion 6.7 is equivalent to
E
[




H(k)H(s) | Lm, Am−1 = 0
]
. (5)
Assumption (5) is not far-fetched: under assumption of no unmeasured con-
founding 4.1, because of Theorem 5.3, the conditional expectation given
Lm, Am−1 = 0, Am of the two factors H(k) and H(s) does not depend on
Am. Assumption 6.7 can be checked empirically by using a preliminary
estimator ψ̃ for ψ∗, regressing the product Hψ̃(k)Hψ̃(s) on Lm, Am, and
investigating whether parameter(s) describing the dependence on Am are
equal to 0.
Rank preservation holds if H(k) does not just mimic Y
(∅)
k as described in
Theorem 5.3, but H(k) is equal to Y
(∅)
k . Assumption of no unmeasured con-









Lm, Am−1 = 0. Under this formulation of no unmeasured confounding and
rank preservation, equation (5) and thus Assumption 6.7 are immediate.
Unfortunately, rank preservation is a very strong assumption, which we do
not wish to make. For a discussion see e.g. Robins (1998b) or Lok (2017).
The following theorem describes the optimal estimator in an example:














2 + ψ6(k −m) + ψ7lvlm
)
(k −m) + ψ8lvlm






Tr(m, k) | Am = 0, Lm
]
m (k −m)− E
[
TTr(m, k) | Am = 0, Lm
]
m2 (k −m)− E
[












Tr(m, k) | Am = 0, Lm
])
(k −m)2 − E
[













with Tr(m, k) the number of treated times between time m and time k, and
~covm
[














(I8 the 8×8 identity matrix), with Γmk,s = cov
[
H(k), H(s) | Lm, Am−1 = 0
]
.


























ψ, θ̂, ~q opt
))
= 0 leads to an optimal estimator ψ̂: any other






= 0 for some ~q, leads to an
asymptotic variance that is at least as large as the asymptotic variance of ψ̂.







= 0 leads to the smallest asymptotic variance of all es-
timators considered in this article (Theorems 6.2 and 6.4), and estimating
θ∗ with pooled logistic regression does not change the asymptotic variance
(Theorem 6.3). ~q opt from Theorem 6.8 therefore leads to the smallest pos-
sible asymptotic variance.
Theorem 6.9 (OPTIMAL ESTIMATOR). Extending Theorem 6.8 to dif-
ferent treatment effect models γ can be done as follows. When choosing
simpler models for γψ, delete the corresponding rows in equation (6) for
~∆m(k) and replace the 8 in I8 by the number of remaining parameters. For
more complicated or different models, notice that the first entry in each row
of ~∆m(k) corresponds to the second entry in each row but with Am = 0 re-
placed by Am = 1. In addition, the model for γ of Theorem 6.8 can easily
be generalized to contain similar terms depending on other covariates; the
optimal estimator then follows similar to Theorem 6.8.
The term Γmk,s and the double robustness term E
[
Hψ(k) | Lm, Am−1 = 0
]
are fixed functions of Lm, but they may depend on ψ. We will use an
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Hψ(k) | Lm, Am−1 = 0
]
. If the treatment initiation model pθ is correctly
specified, the estimating equations are unbiased for any fixed value of ψ̃. In
our application (Section 9), a candidate for ψ̃ is motivated by the estimator
which is optimal among those with ~q km only non-zero for k = m + 12. This
can be shown to lead to q satisfying
~∆m(m+ 12) = Var
[







Additionally, replacing the conditional variance of H(m+ 12) by a working
identity covariance matrix gives q̃ m+12m =
~∆m(m + 12). This leads to valid
estimates ψ̃: stacking the estimating equations with this q̃ with estimating
equations for the parameters in ~∆m, results in unbiased estimating equations
(Theorem 5.4).
The (generalized) inverse of ~covm
[
HI8 | Lm, Am−1 = 0
]
equals the (gen-
eralized) inverse of the conditional covariance matrix of H with each entry
replaced by the entry times I8.
The optimal estimator requires estimating conditional expectations. In
small samples this may be an issue, but as for many efficient estimators (see
e.g. Newey 1993, 1990, Hahn 1998, or Tsiatis 2006), it does not lead to a
larger asymptotic variance if all models are correctly specified:
Theorem 6.10 Suppose ψ̃2 is a preliminary estimator of ψ∗ which is the
result of unbiased estimating equations PnG̃(ψ2) = 0, θ̂ is an estimator of
θ∗ from a correctly specified pooled logistic regression model with estimating
equations PnU(θ) = 0, and Eξ
[
Hψ(k) | Lm, Am−1 = 0
]
and ~q optψ,ξ are pa-
rameterized by ξ, with ξ∗ the true ξ when ψ = ψ∗, which can be estimated
using estimating equations PnJ(ξ, ψ) = 0 with EJ (ξ∗, ψ∗) = 0. Then, under
regularity conditions, solving ψ̂ from the unbiased estimating equations
Pn
(
G∗(ψ, θ, ~q optm,ψ2,ξ) G̃(ψ2) J(ξ, ψ2) U(θ)
)
= 0,
results in the same asymptotic variance for ψ̂ as using the true (but un-





ψ, θ̂, ~q opt
))
= 0.
Solving these estimating equations simultaneously leads to the same esti-
mator ψ̂ as plugging in (ψ̃2, θ̂, ξ̂) into the estimating equations for ψ∗ and
then solving for ψ̂. Theorem 6.10 implies that, if all models are correctly
specified, the resulting ψ̂ is optimal within the classes studied here.
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In practice, instead of estimating Γmk,s = cov
[
H(k), H(s) | Lm, Am−1 = 0
]
,
one may choose to use a so-called working covariance matrix, and replace Γm
by, for example, the identity matrix. This can be compared with working
correlation matrices in generalized linear models as in Zeger et al. (1988).
As for generalized linear models, the resulting estimator is not optimal, but
consistency, asymptotic normality and double robustness are not affected.
Theorem 6.11 (CONSISTENCY OF THE BOOTSTRAP). Under regu-
larity conditions, the bootstrap for all estimators above is consistent under
the conditions already adopted for consistency and asymptotic normality.
7 Applying these methods: estimation steps
7.1 Implementation: general remarks
Section 7 details the implementation of the estimators proposed in this ar-
ticle. The model for γ here is Example 3.3 model (1), but the methods can
easily be adapted to other treatment effect models. Models that are linear
in ψ are especially attractive because they lead to estimating equations that
are linear in ψ and that are therefore easy to solve. SAS 9.1.3 (SAS Institute
Inc., Cary, North Carolina, USA) was used for all analyses. The SAS code
is available from the author.
As in Lok and DeGruttola (2012), we adopt a pooled logistic regression
model for the treatment prediction model, pθ(m). As the outcome Yk one
could choose either the CD4 count itself or the CD4 count increase between
month m and month k. From Definition 3.1 of the treatment effect, the
same quantity is estimated whether Yk is the CD4 count or the CD4 count





k the same way, so the CD4m terms in γ cancel. The CD4 count increase
between month m and month k likely reflects more than the CD4 count
at month k the effect of treatment taken between month m and month k,
i.e. less noise is expected. Thus, the CD4 count increase between month
m and month k was used as the outcome for all estimators that are not
doubly robust. For doubly robust estimators, subtracting CD4m from the
outcome CD4k does not affect the point estimates, since the same covari-
ate is included in Lm; subtracting CD4m from CD4k would affect both Yk
and E
[
H(k) | Lm, Am−1 = 0
]
in the same way, so the CD4m terms in the
estimating equations cancel.
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7.2 A preliminary estimator ψ̃
As a preliminary estimator ψ̃, necessary to implememt the optimal estima-
tor, we used a doubly robust version of the estimator from Lok and De-
Gruttola (2012). This choice of ~q km is the same as in Theorem 6.9, but with
qkm = 0 for k 6= m + 12, and with the ~covm
[
HI3 | Lm, Am−1 = 0
]
replaced
by identity matrices. Under a homoscedasticity condition, this choice of q is
optimal within the class of estimating equations with ~q km = 0 for k 6= m+12.
In the models for q, E[Tr(m,m+ 12) | Lm, Am = 0], etc., we first estimated
pr(Tr(m,m + 12) 6= 0 | Lm, Am = 0) using logistic regression, and then,
conditional on Tr(m,m + 12) 6= 0 and Am = 0, regressed Tr(m,m + 12)
on the covariates Lm. In the presence of censoring, we restricted the regres-
sions to patients still in follow-up at month m+ 12. Misspecification of q of
the preliminary estimator does not affect asymptotic optimality or double
robustness of the optimal estimator that makes use of it. In finite samples
it may affect the variance.
With this treatment effect model, H(m + 12) = Ym+12 − (ψ1 + ψ2T +
ψ3T
2)Tr(m,m + 12), and to estimate E
[
H(m+ 12) | Lm, Am−1 = 0
]
, we
considered each term in this expression separately, leaving in ψ.
For E[Tr(m,m + 12) | Lm, Am−1 = 0], we used the same approach as for
E[Tr(m,m+12) | Lm, Am = 0]. In the presence of censoring, we used Inverse
Probability of Censoring Weighting (IPCW, see e.g. Robins et al. 1995)
starting at month m. With Cp = 0 indicating a patient was uncensored at











This procedure leads to estimating equations that are linear in ψ and
thus easy to solve.
7.3 The optimal estimator
The mimicking outcome H(k) was first estimated by Hψ̃(k). Theorem 5.3
facilitates specification of a model for E[H(k) | Lm, Am−1 = 0]. Linear re-
gression was used to estimate E[H(k) | Lm, Am−1 = 0]. In the presence
of censoring, we used IPCW, as for the preliminary estimator. This leads
to an estimate Ê[H(k) | Lm, Am−1 = 0] based on estimating equations.
Optimality depends on correct specification of E[H(k) | Lm, Am−1 = 0],
but if the treatment initiation model pθ is correctly specified, consistency
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and asymptotic normality do not (because of double robustness). In the
model for ∆, E[Tr(m, k) | Lm, Am = 0] etcetera, the same approach as in
Section 7.2 was used: first pr(Tr(m, k) 6= 0 | Lm, Am = 0) was estimated
using logistic regression; then, conditional on Tr(m, k) 6= 0 and Am = 0,
Tr(m, k) was regressed on the covariates Lm. In the presence of censoring,
the regression was restricted to patients still in follow-up at month k. In the
simulations, ~covm
[
HI3 | Lm, Am−1 = 0
]
(Theorem 6.9) does not depend on
Lm. In the application, a working model not depending on Lm was used
for ~covm
[
HI3 | Lm, Am−1 = 0
]
, similar to a working covariance matrix. Γmk,s
was estimated by the empirical average over all patients of{
Hψ̃(k)− Ê[H(k) | Lm, Am−1 = 0]
}{
Hψ̃(s)− Ê[H(s) | Lm, Am−1 = 0]
}
.
Alternatively, also after plugging in ψ̃, we could have used techniques sim-
ilar to GEE to estimate a working covariance matrix. In the presence of
censoring, we added Cmax(k,s) = 0 to the conditioning event. Misspecifica-
tion of q (through ∆ or ~covm
[
HI3 | Lm, Am−1 = 0
]
) leads to a suboptimal
estimator, but (Theorem 6.10) does not affect double robustness, because
all specifications leading to q only depend on Lm and parameters solving
estimating equations.
This procedure leads to estimating equations that are linear in ψ and
thus easy to solve.
7.4 For comparison, a naive choice
For comparison, we implemented two non-doubly-robust estimators, based
on Theorem 5.4 and not using the optimality theory developed here. For
these Theorem 2-based estimators, since in our application (Section 9) in-
terest lies in the effect of one year of treatment, ~q km = 0 for k 6= m+ 12, and
the ~q m+12m were as follows, with CD4m the CD4 count at month m, injdrug
an indicator of whether the patient ever injected drugs at or before the first
visit, lvlm the log10 viral load at month m, and firstvisitm an indicator for

























We simulated data with monthly visits, and based choices for the simulated
data on the AIEDRP data on HIV infected patients, described in Section 9.
We used an auto-regressive model for the course of the CD4 count, which
may be more realistic in months 6-30 than before month 6, given the different
behavior of CD4 counts in the first 6 months since HIV infection (Web-
Appendix C). Therefore, we simulated data in months 6-30, and estimated
the effect of treatment initiation in months 6-18. Simulations are detailed
in Web-Appendix C.
We simulated two scenarios: 1.: 1000 datasets with 1000 observations
each, and 2.: 500 datasets with 5000 observations each. We fitted model
(1) with 2 parameters, (ψ1, ψ2), and 3 parameters, (ψ1, ψ2, ψ3). In these
simulations, the true ψ3 equals 0. Since in our application interest focused
on the effect of one year of treatment, we restricted the estimating equations
to k = m + 1, . . . ,m + 12 so as to rely less on model specification. Table 1
shows the root mean squared errors of the different estimators described in
Sections 6 and 7. Web-Appendix C.2 describes the models fitted for the
nuisance parameters.
Table 1 shows great improvements from applying our theory in compar-
ison with a naive choice of estimating equations (Table 1 estimators 1a. and
1b., described in Section 7.4). Choosing q without using optimality theory
can lead to useless inference. Making the estimator doubly robust (estimator
3.) results in improvements of the mean squared errors in the 3-parameter
model. Not restricting the analysis to k = m + 12 (estimators 4. and 5.)
results in improvements overall, and our estimator with optimal asymptotic
properties (estimator 5.) performs best in the simulations.
We also calculated the 2.5% and 97.5% quantiles (over the datasets) of
the estimated parameters for estimators 2., 3., 4., and 5. For all parameters,
the truth was in between these quantiles.
For n = 1000, we also investigated choosing sparser models (Web-Appen-
dix C.2) in the expressions for the prediction of treatment duration (for q and
for the doubly robust term). Choosing sparser models made little difference
for estimators 3., 4., and 5 in Table 1. For estimator 2. in Table 1, sparser
models for q led to substantially larger mean squared errors (results not
shown).
Figure 1 shows the results for the datasets with 1000 observations. Fig-
ure 1 compares the performance of estimators of the effect of treatment on
the 1-year increase in the CD4s count due to treatment initiated at the dif-
ferent months. For example, for month 11, this is the root mean squared
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error for the expected difference in CD4 count at month 23=12+11 between
1. initiating ART at month 11 versus 2. never initiating ART. Figure 1 does
not include the naive estimators (1a. and 1b. in Table 1), since those per-
form much worse and incorporating them makes a comparison of the other
estimators impossible. The same pattern appears as in Table 1, with the
optimal estimator performing best.
9 The effect of ART in HIV infected patients dur-
ing acute and early HIV infection
ART is the standard of care for HIV infection. Guidelines regarding ART ini-
tiation have been changing, with patients initiating ART earlier (Thompson
et al. 2010, Panel on Antiretroviral Guidelines for Adults and Adolescents
2016, World Health Organization 2016), often even at the time of diagnosis,
especially in the developed world.
The effect of ART in the early and acute stages of HIV infection was stud-
ied in Lok and DeGruttola (2012) using a preliminary version of our article;
we aim to estimate the effect of ART with more robustness and precision.
Given the limited data on early HIV infection, this is a timely question in
HIV research. We estimate how the effect on immune reconstitution of ini-
tiating one year of ART depends on the time between the estimated date
of HIV infection and ART initiation. The effect on immune reconstitution
of one year of ART initiated m months after infection, is measured as the
CD4 count at month m+12 with ART initiated at month m versus the CD4
count at month m+ 12 without ART. Of particular interest is the effect of






The results of our investigation are important, since ART initiation soon
after infection may not only improve a patient’s own outcomes, but also
reduces the risk that a patient’s HIV infection is spread to others (Cohen
et al. 2011, Granich et al. 2009, DeGruttola et al. 2008). Furthermore,
the CDC is encouraging HIV testing (Satcher-Johnson et al. 2010), leading
to earlier HIV diagnoses, so more treatment initiation decisions need to be
made during early and acute infection. There is not a lot of evidence of
clinical benefit for initiating ART this early, with likely a relatively small
number of patients in the START trial (The INSIGHT START Study Group
2015) in acute or early infection at baseline. Our investigations shed light
on the effect of efforts to diagnose HIV early, if early diagnosis is combined
with immediate ART initiation as currently recommended.
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We apply our estimators to the observational AIEDRP (Acute Infection
and Early Disease Research Program) Core01 data, using data on 1762 HIV
infected patients diagnosed during acute and early infection (Hecht et al.
2006). Dates of infection are estimated using an algorithm that incorporates
clinical and laboratory data (Hecht et al. 2006, Smith et al. 2006). Lok
and DeGruttola (2012) showed that in the AIEDRP, ART use depends on
covariates such as the current CD4 count that are prognostic for the outcome
CD4 count; and that this leads to substantial confounding by indication.
In this HIV application, K + 1 is 24 months. 0 is the estimated date of
HIV infection, although visits may be missed during follow-up and partic-
ularly in the earliest months of infection. To account for missed visits, we
include the visit pattern (in which months a visit took place) as a measured
covariate. Y , A, and L are measured at multiple time points that vary across
patients. For L we use the average measurement within the given month;
if this is missing at month m, Lm is coded as missing, a possible covariate
value. Am cannot be missing because we assume that treatment can only
start at visits and then it is always recorded. We impute missing data on
the outcomes Yk, after the first visit and until censoring, by interpolation,
except for visits just prior to onset of treatment, for which we carry the last
observation forward, in order to avoid using post-treatment information to
impute outcomes prior to treatment. We assumed:
Assumption 9.1 (Parameterization of coarse structural nested mean model).











with (k −m) the treatment duration from month m to month k.





, Assumption 9.1 suffices. Specifying γmk for k < 12
and k > m + 12 might lead to greater precision, but increases the risk
of model misspecification. The restriction to these values of k implies
that in assumption of no unmeasured confounding 4, k can be similarly
restricted. For estimation, every sum over k is then also restricted to
k = (m+ 1) ∨ 12, . . . , (m+ 12) ∧ (K + 1).
Because treatment is assumed to only change at visit times, the estimat-
ing equations include 1visit(m), an indicator of whether a visit took place at
time m. For loss to follow-up, we assumed missing at random (Rubin 1976)
and applied inverse probablity of censoring weighting (Robins et al. 1995).
Web-Appendix D describes the nuisance parameter models.
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Table 2 provides estimates and bootstrap 95% confidence intervals based
on the AIEDRP data, for the same estimators as described in Section 8. Ta-
ble 2 shows that importantly, all estimators based on the optimality theory of
the current article lead to much narrower 95% confidence intervals than the
estimators based on Theorem 5.4 with q chosen in a naive way as described
in Section 7.4. Both naive estimators lead to irrelevant estimators in the
3-parameter model, due to extremely wide confidence intervals. The same
is true for the second naive estimator in the 2-parameter model. Double
robustness does not lead to narrower confidence intervals in the AIEDRP
data (compare estimators 2. and 3.). Estimator 5., which would be opti-
mal without censoring and under homoscedasticity assumption 6.7, leads to
much wider confidence intervals than Estimator 4. For the AIEDRP data,
Estimator 4., which is similar to the optimal estimator but with working
identity covariance matrices, leads to the narrowest confidence intervals.
Figure 2 compares the performance of estimators of the effect of ART
treatment on the one-year increase in the CD4 count due to ART initiated at
the different months since the estimated date of HIV infection. For example,
for month 11, the quantity in Figure 2 is the estimated expected difference
in the CD4 count at month 23=11+12, comparing initiating ART at month
11 versus never initiating ART. To facilitate the comparison of the other
estimators, Figure 2 does not include the naive estimators of Section 7.4,
which performed much worse. As in Table 2, Estimator 4., with a working
identity covariance matrix, leads to the best precision.
Table 2 also describes the results of a sensitivity analysis (details in Web-
Appendix D). In this sensitivity analysis, treatment initiation and dropout
are modeled using model selection techniques. While model selection in prin-
ciple invalidates the confidence intervals, this sensitivity analysis indicates
that the results are somewhat sensitive to model specification.
The estimated effect of one year of ART initiated during acute and early
HIV infection is substantial and significant. It decreases somewhat when the
time between the estimated date of infection and ART initiation increases,
but this trend is insignificant.
10 Discussion
Causal inference methods to analyze observational data require untestable
assumptions, so it is important to analyze longitudinal observational data
using different methods and compare the results. This requires a variety of
methods, and the further development of structural nested models, as an
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addition to the wider applied class of weighting methods.
Both in the simulation study and in the HIV application, most of the
naive coarse structural nested mean model (coarse SNMM) estimators led to
useless inference. This could realistically happen in practice if the nuisance
function ~q is chosen without knowledge of optimality theory, and motivated
this article. In the HIV application, the naive estimators were so imprecise
that it was important to not use a naive preliminary estimator in the first
step for the optimal estimator.
Our theory resulted in substantially improved precision of coarse SN-
MMs. In the simulation study, the optimal doubly robust estimator resulted
in useful inference, and performed best. In the HIV application, our meth-
ods also substantially improved precision. In the HIV application, the best
performance was by a doubly robust estimator related to the optimal estima-
tor, but using working identity covariance matrices, similar to the identity
working covariance matrices approach in Generalized Estimating Equations
(Tsiatis 2006, Section 4.6). The suboptimal behavior of the optimal estima-
tor may have several causes. It could be due to the combination of limited
sample size and censoring. It could also be due to model misspecification of
the nuisance parameter models, especially of ~covm[HI3|Lm, Am−1 = 0]. We
focused on coarse SNMMs with a time-varying outcome; Web-appendix B
shows how the calculations simplify considerably with an outcome measured
at the end of the study.
Inverse probability of treatment weighting of marginal structural models
(Robins et al. 2000, Hernán et al. 2000) can only be used to estimate how a
treatment effect depends on baseline covariates. It would be interesting to
know whether coarse SNMMs provide more precise estimators than marginal
structural models when interest lies in this scenario. Efficiency gains of
coarse SNMMs could be expected, because SNMMs use all observed data,
whereas if a saturated outcome model is used, marginal structural models
use only the data that is consistent with the specific treatment regime. Our
investigation is the first step in the comparison between coarse SNMMs
and marginal structural models: we optimized of the performance of coarse
SNMMs.
A promising area for future research are estimation methods when the
number of potential confounders is large. Regularization methods such as
LASSO are then the obvious candidates to estimate the propensity scores
and the conditional expectation of H, assuming e.g. that only a limited
number of confounders truly contribute. Since our proposed estimators are
doubly robust, the estimating equations satisfy the orthogonality or immu-
nization condition of Chernozhukov et al. (2015). This can be seen since, as
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a function of one of the two nuisance parameter models, say ξ, the estimating
function has expectation 0 for all ξ when the other parameter, say θ, is held
at its true value. Thus, provided that a high-quality regularization method
is used, it can be expected that if both nuisance parameter models are cor-
rectly specified, asymptotically correct inference can be obtained by using
the methods proposed in Chernozhukov et al. (2015). Correct specifica-
tion of nuisance parameter models will be more likely for reasonable sample
sizes if regularization is used, allowing for more elaborate candidate mod-
els. In addition, Yang and Lok are investigating semiparametric efficiency
in the presence of censoring; this will involve investigating semiparametric
efficient estimation as in e.g. Tsiatis (2006) and Hahn (1998), but adapted
to treatment effects that depend on time-dependent pre-treatment covari-
ates. Targeted maximum likelihood estimation could be another option to
investigate semiparametric efficiency.
This article has limitations. As in traditional structural nested mean
models, we have assumed that all confounders are measured. This assump-
tion cannot be tested using the available data. Subject matter experts have
to judge whether the data analyst included all covariates that are predictive
of both treatment initiation and outcome. Moreover, in our HIV application
we have assumed that a simple treatment effect model is correctly speci-
fied. Yang and Lok (2016) tested this assumption, and concluded that the
AIEDRP data do not provide evidence that this assumption is violated; how-
ever, this may be due to a limited sample size. Investigating the properties
of the proposed estimator when the treatment effect model is misspecified
is an interesting topic for future research. In addition, our calculations for
optimality are restricted to linear treatment effect models. Future research
may involve nonlinear treatment effect models; for this Newey (1990), al-
though mainly aimed at estimating the effect of point exposures, may be
useful. Moreover, our estimators are likely not optimal in the presence of
censoring. They do remain doubly robust if censoring is missing at random
(Rubin 1976) and the model for censoring is correctly specified. In our HIV
application, which includes censoring, our methods still led to remarkable
variance reductions. In addition, one or more of the models for the nui-
sance parameters may be misspecified. Only the treatment initiation model
and the outcome regression model affect consistency and asymptotic nor-
mality, and double robustness implies that misspecification of one of these
two models preserves consistency and asymptotic normality.
We conclude that the precision of estimators for coarse structural nested
mean models depends substantially on the estimating equations chosen. The
substantial improvement we found by choosing optimal estimating equations
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suggests that the use of optimal estimators may encourage more widespread
use of coarse structural nested mean models.
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Figure 1: Square root MSE of estimators 2.-5. in the simulation study. For
example, for month 11, the quantity in the figure is the estimate for the
square root MSE for the expected difference in the CD4 count at month
23=11+12 between starting ART at month 11 versus never starting ART.






























































Figure 2: Estimates of the effect of one year of ART: AIEDRP data. For
example, for month 11, the quantity in the figure is the estimate for the
expected difference in the CD4 count at month 23=11+12 between starting
ART at month 11 versus never starting ART.
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